{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:44:18Z","timestamp":1780361058600,"version":"3.54.1"},"reference-count":81,"publisher":"Informa UK Limited","issue":"9","funder":[{"DOI":"10.13039\/501100010628","name":"Universidad de La Sabana","doi-asserted-by":"publisher","award":["MED-355-2023"],"award-info":[{"award-number":["MED-355-2023"]}],"id":[{"id":"10.13039\/501100010628","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Neurotherapeutics"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1080\/14737175.2024.2374024","type":"journal-article","created":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T05:23:01Z","timestamp":1721712181000},"page":"837-848","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":5,"title":["Profiling the combination of bupropion and dextromethorphan as a treatment option for major depressive disorder"],"prefix":"10.1080","volume":"24","author":[{"given":"Joseph","family":"Blanco","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacology, Evidence-Based Therapeutics Group, Faculty of Medicine, Universidad de La Sabana and Cl\u00ednica Universidad de La Sabana, Ch\u00eda, Cundinamarca, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Quimbaya","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Evidence-Based Therapeutics Group, Faculty of Medicine, Universidad de La Sabana and Cl\u00ednica Universidad de La Sabana, Ch\u00eda, Cundinamarca, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Mena","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Evidence-Based Therapeutics Group, Faculty of Medicine, Universidad de La Sabana and Cl\u00ednica Universidad de La Sabana, Ch\u00eda, Cundinamarca, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seetal","family":"Dodd","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Universidad de La Sabana, Ch\u00eda, Colombia"},{"name":"IMPACT - The Institute for Mental and Physical Health and Clinical Translation, School of Medicine, Deakin University, Barwon Health, Geelong, Australia"},{"name":"Centre for Youth Mental Health, University of Melbourne, Parkville, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa-Helena","family":"Bustos","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Evidence-Based Therapeutics Group, Faculty of Medicine, Universidad de La Sabana and Cl\u00ednica Universidad de La Sabana, Ch\u00eda, Cundinamarca, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,7,22]]},"reference":[{"issue":"21","key":"e_1_3_6_3_1","first-page":"591","article-title":"Diagnostic and statistical manual of mental disorders","volume":"21","author":"Edition F.","year":"2013","unstructured":"Edition F. Diagnostic and statistical manual of mental disorders. Am Psychiatr Assoc. 2013;21(21):591\u2013643.","journal-title":"Am Psychiatr Assoc"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2017.4602"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0954579414001151"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.65"},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-018-0090-3"},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.2051-5545.2010.tb00298.x"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-022-01661-0"},{"key":"e_1_3_6_10_1","doi-asserted-by":"publisher","DOI":"10.1503\/jpn.100002"},{"key":"e_1_3_6_11_1","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci11101298"},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.9058se1c.04gry"},{"key":"e_1_3_6_13_1","doi-asserted-by":"publisher","DOI":"10.7326\/m22-1603"},{"key":"e_1_3_6_14_1","doi-asserted-by":"publisher","DOI":"10.3109\/15622975.2014.1001786"},{"key":"e_1_3_6_15_1","doi-asserted-by":"publisher","DOI":"10.7326\/m15-2570"},{"key":"e_1_3_6_16_1","doi-asserted-by":"publisher","DOI":"10.12740\/PP\/OnlineFirst\/132496"},{"key":"e_1_3_6_17_1","first-page":"4","article-title":"Auvelity (dextromethorphan\/bupropion)","volume":"122","author":"Abuzoor A","year":"2023","unstructured":"Abuzoor A, El-Alfy AT, Busse K. Auvelity (dextromethorphan\/bupropion). WMJ. 2023;122:4.","journal-title":"WMJ"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.9758\/cpn.23.1081"},{"key":"e_1_3_6_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-019-0460-3"},{"key":"e_1_3_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(22)02080-3"},{"key":"e_1_3_6_21_1","doi-asserted-by":"publisher","DOI":"10.1080\/1364557032000119616"},{"key":"e_1_3_6_22_1","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v9.i31.9350"},{"key":"e_1_3_6_23_1","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2023.11810"},{"key":"e_1_3_6_24_1","doi-asserted-by":"publisher","DOI":"10.31887\/DCNS.2008.10.4\/mhtrivedi"},{"key":"e_1_3_6_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2034954"},{"key":"e_1_3_6_26_1","doi-asserted-by":"publisher","DOI":"10.1021\/acschemneuro.7b00055"},{"key":"e_1_3_6_27_1","unstructured":"Drugbank. Bupropion 2024. [cited 2024 Apr 3]. Available from: https:\/\/go.drugbank.com\/drugs\/DB01156"},{"key":"e_1_3_6_28_1","unstructured":"Drugbank. Dextromethorphan 2024. [cited 2024 Mar 30]. Available from: https:\/\/go.drugbank.com\/drugs\/DB00514"},{"key":"e_1_3_6_29_1","volume-title":"Dextromethorphan","author":"Oh S","year":"2024","unstructured":"Oh S, Agrawal S, Sabir S, et al. Dextromethorphan. Treasure Island (FL): StatPearls; 2024."},{"key":"e_1_3_6_30_1","doi-asserted-by":"publisher","DOI":"10.47750\/pnr.2022.13.S06.087"},{"key":"e_1_3_6_31_1","unstructured":"PubChem. Bupropion 2024. [cited 2024 Mar 15]. Available from: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Bupropion"},{"key":"e_1_3_6_32_1","first-page":"1","volume-title":"Profiles of drug substances, excipients and related methodology","author":"Khan SR","year":"2016","unstructured":"Khan SR, Berendt RT, Ellison CD, et al. Chapter one - bupropion hydrochloride. In: Brittain H, editor. Profiles of drug substances, excipients and related methodology. Vol. 41. Milford, New Jersey, USA: Academic Press; 2016. p. 1\u201330."},{"key":"e_1_3_6_33_1","unstructured":"PubChem. Dextromethorphan hydrobromide monohydrate 2024. [cited 2024 Mar 30]. Available from: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/6700-34-1"},{"key":"e_1_3_6_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2016.04.010"},{"key":"e_1_3_6_35_1","doi-asserted-by":"publisher","DOI":"10.1080\/15563650701668625"},{"issue":"3","key":"e_1_3_6_36_1","first-page":"962","article-title":"Dextromethorphan and its metabolite dextrorphan block alpha3beta4 neuronal nicotinic receptors","volume":"293","author":"Hernandez SC","year":"2000","unstructured":"Hernandez SC, Bertolino M, Xiao Y, et al. Dextromethorphan and its metabolite dextrorphan block alpha3beta4 neuronal nicotinic receptors. J Pharmacol Exp Ther. 2000;293(3):962\u2013967.","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_3_6_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2007.06.013"},{"key":"e_1_3_6_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-023-01032-5"},{"key":"e_1_3_6_39_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.925879"},{"key":"e_1_3_6_40_1","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2021.685201"},{"key":"e_1_3_6_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2009.04.021"},{"key":"e_1_3_6_42_1","volume-title":"ASCP 2018 Annual Meeting: Treatment of Psychiatric Illness Across the Lifespan. 2018. ASCP Annual Meeting","author":"O\u2019Gorman C","year":"2018","unstructured":"O\u2019Gorman C, Jones A, Kennon K, et al. AXS-05 for neuropsychiatric disorders: scientific rationale and clinical development [abstract no. T16 plus poster]. In: ASCP 2018 Annual Meeting: Treatment of Psychiatric Illness Across the Lifespan. 2018. ASCP Annual Meeting; Miami Beach, Fl; 2018."},{"key":"e_1_3_6_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-022-00968-4"},{"key":"e_1_3_6_44_1","doi-asserted-by":"publisher","DOI":"10.1586\/14737175.6.9.1249"},{"key":"e_1_3_6_45_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40267-023-01009-w"},{"key":"e_1_3_6_46_1","unstructured":"AXSOME Therapeutics Inc. AUVELITY (dextromethorphan hydrobromide and bupropion hydrochloride) extended-release tablets: US prescribing information 2022. [cited 2024 Mar 15]. Available from: https:\/\/www.auvelity.com\/"},{"key":"e_1_3_6_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2009.05.015"},{"key":"e_1_3_6_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/bs.apha.2020.04.004"},{"issue":"1666","key":"e_1_3_6_49_1","first-page":"201","article-title":"Dextromethorphan\/bupropion (auvelity) for depression","volume":"64","author":"The Medical Letter","year":"2022","unstructured":"The Medical Letter. Dextromethorphan\/bupropion (auvelity) for depression. Med Lett Drugs Ther. 2022;64(1666):201\u2013203.","journal-title":"Med Lett Drugs Ther"},{"key":"e_1_3_6_50_1","doi-asserted-by":"publisher","DOI":"10.1017\/s1092852919001470"},{"key":"e_1_3_6_51_1","unstructured":"BioSpace. Axsome therapeutics announces FDA approval of AUVELITY\u2122 the first and only oral NMDA receptor antagonist for the treatment of major depressive disorder in adults. 2022 [cited 2024 Mar 30]. Available from: https:\/\/www.biospace.com\/article\/releases\/axsome-therapeutics-announces-fda-approval-of-auvelity-the-first-and-only-oral-nmda-receptor-antagonist-for-the-treatment-of-major-depressive-disorder-in-adults\/"},{"key":"e_1_3_6_52_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.21080800"},{"key":"e_1_3_6_53_1","volume-title":"175th Annual Meeting of the American Psychiatric Association","author":"Jones A","year":"2022","unstructured":"Jones A, Anderson A, Tabuteau H. Efficacy and safety of AXS-05 in the prevention of relapse in patients with treatment-resistant depression: results from the MERIT trial [abstract no. 40]. In: 175th Annual Meeting of the American Psychiatric Association; New Orleans, USA; 2022."},{"key":"e_1_3_6_54_1","volume-title":"American Society of Clinical Psychopharmacology Annual Meeting","author":"Jones A","year":"2022","unstructured":"Jones A, Streicher C, Thomas Z. AXS-05 (dextromethorphan-bupropion) improves depressive symptoms and functioning in patients with one prior treatment failure: results from the EVOLVE long-term, open-label study [abstract no. W56]. In: American Society of Clinical Psychopharmacology Annual Meeting; Arizona, USA; 2022."},{"key":"e_1_3_6_55_1","unstructured":"ClinicalTrials.gov. An Evaluation of AXS-05 for the Treatment of TRD in treatment-adherent patients (TARGET): NCT04971291 2021. [cited 2024 Mar 30]. Available from: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04971291#wrapper"},{"key":"e_1_3_6_56_1","unstructured":"BioSpace. Axsome therapeutics announces topline results of the STRIDE-1 Phase 3 trial in treatment resistant depression and expert call to discuss clinical implications. 2020 [cited 2024 Apr 15]. Available from: https:\/\/www.biospace.com\/article\/releases\/axsome-therapeutics-announces-topline-results-of-the-stride-1-phase-3-trial-in-treatment-resistant-depression-and-expert-call-to-discuss-clinical-implications\/"},{"key":"e_1_3_6_57_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.21m14345"},{"key":"e_1_3_6_58_1","volume-title":"174th Annual Meeting of the American Psychiatric Association","author":"Jones A","year":"2021","unstructured":"Jones A, O\u2019Gorman C, Tabuteau H. Sustained efficacy and long-term safety of AXS-05, an oral NMDA receptor antagonist in major depressive disorder: COMET study results [abstract no. 28]. In: 174th Annual Meeting of the American Psychiatric Association; Online, USA; 2021."},{"key":"e_1_3_6_59_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2019.00294"},{"key":"e_1_3_6_60_1","unstructured":"European Medicines Agency. Valdoxan 2009. [cited 2024 Mar 20]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/valdoxan"},{"key":"e_1_3_6_61_1","unstructured":"Food and Drug Administration. Cymbalta. 2008. Available from: https:\/\/wwwaccessdatafdagov\/drugsatfda_docs\/label\/2010\/022516lblpdf"},{"key":"e_1_3_6_62_1","unstructured":"Food and Drug Administration. Celexa. Available from 2009. Available from: https:\/\/wwwaccessdatafdagov\/drugsatfda_docs\/label\/2009\/020822s037 021046s015lblpdf"},{"key":"e_1_3_6_63_1","unstructured":"Food and Drug Administration. Pristiq. Available from 2011. Available from: https:\/\/wwwaccessdatafdagov\/drugsatfda_docs\/label\/2012\/021992s030lblpdf"},{"key":"e_1_3_6_64_1","unstructured":"Food and Drug Administration. Wellbutrin. 2017. Available from: https:\/\/wwwaccessdatafdagov\/drugsatfda_docs\/label\/2017\/018644s052lblpdf"},{"key":"e_1_3_6_65_1","unstructured":"Food and Drug Administration. Lexapro. 2017. Available from: https:\/\/wwwfdagov\/media\/135185\/download"},{"key":"e_1_3_6_66_1","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000035871"},{"key":"e_1_3_6_67_1","unstructured":"Food and Drug Administration. Prozac 1987. [cited 2024 Mar 30]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/018936s091lbl.pdf"},{"key":"e_1_3_6_68_1","unstructured":"Food and Drug Administration. Serzone 2002. [cited 2024 Mar 15]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2003\/020152_S031_SERZONE_PRNTLBL.pdf"},{"key":"e_1_3_6_69_1","unstructured":"Food and Drug Administration. Remeron 2007. [cited 2024 Feb 18]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/020415s023s024.pdf"},{"key":"e_1_3_6_70_1","unstructured":"Food and Drug Administration. Paxil 2012. [cited 2024 Apr 20]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/020031s067%2C020710s031.pdf"},{"key":"e_1_3_6_71_1","unstructured":"Food and Drug Administration. Fetzima 2017. [cited 2024 Feb 15]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/204168s004lbl.pdf"},{"key":"e_1_3_6_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2023.08.026"},{"key":"e_1_3_6_73_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.20220434"},{"key":"e_1_3_6_74_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.23cr15139"},{"key":"e_1_3_6_75_1","unstructured":"EMC. Edronax 2024. [cited 2024 Mar 3]. Available from: https:\/\/www.medicines.org.uk\/emc\/product\/1578\/smpc#UNDESIRABLE_EFFECTS"},{"key":"e_1_3_6_76_1","unstructured":"Food and Drug Administration. Effexor 2008. [cited 2024 Mar 3]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/020151s051lbl.pdf"},{"key":"e_1_3_6_77_1","unstructured":"Food and Drug Administration. Zoloft 2016. [cited 2024 Mar 24]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/019839s74s86s87_20990s35s44s45lbl.pdf"},{"key":"e_1_3_6_78_1","unstructured":"Food and Drug Administration. Trintellix 2017. [cited 2024 Apr 3]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/204447s017lbl.pdf"},{"key":"e_1_3_6_79_1","unstructured":"National Institute for Health and Care Excellence. Depression in adults: treatment and management. 2022 [cited 2024 May 6]. Available from: https:\/\/www.nice.org.uk\/guidance\/ng222"},{"key":"e_1_3_6_80_1","doi-asserted-by":"publisher","DOI":"10.1177\/0706743716659417"},{"issue":"6","key":"e_1_3_6_81_1","first-page":"397","article-title":"Combination antidepressants - use by GPs and psychiatrists","volume":"40","author":"Horgan D","year":"2011","unstructured":"Horgan D, Dodd S. Combination antidepressants - use by GPs and psychiatrists. Aust Fam Physician. 2011;40(6):397\u2013400.","journal-title":"Aust Fam Physician"},{"key":"e_1_3_6_82_1","doi-asserted-by":"publisher","DOI":"10.1586\/14737175.8.9.1299"},{"key":"e_1_3_6_83_1","doi-asserted-by":"publisher","DOI":"10.1080\/15622975.2020.1851052"}],"container-title":["Expert Review of Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737175.2024.2374024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T10:22:12Z","timestamp":1735294932000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14737175.2024.2374024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,22]]},"references-count":81,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["10.1080\/14737175.2024.2374024"],"URL":"https:\/\/doi.org\/10.1080\/14737175.2024.2374024","relation":{},"ISSN":["1473-7175","1744-8360"],"issn-type":[{"value":"1473-7175","type":"print"},{"value":"1744-8360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,22]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iern20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iern20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-05-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}